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Purpose: The efficacy of exclusive enteral nutrition (EEN) with a polymeric diet has not been confirmed in Korean 
pediatric patients with Crohn’s disease (CD). This study aimed to compare the effectiveness of EEN with a specific 
polymeric diet (EncoverⓇ) and corticosteroids (CSs) for the induction of remission in Korean pediatric CD patients.
Methods: We retrospectively compared data from 51 pediatric CD patients who underwent induction therapy with 
EEN (n=19) or CSs (n=32) at Severance Children’s Hospital or Incheon St. Mary’s Hospital in Korea. The primary 
endpoint of this study was the rate of clinical remission, defined as a Pediatric Crohn’s Disease Activity Index (PCDAI) 
score ＜10, after 8 weeks of induction treatment. Clinical, laboratory, and growth data at post-induction as well as 
their changes from baseline were also compared between groups.
Results: After 8 weeks of induction therapy, clinical remission rates were 78.9% (15/19) and 65.6% (21/32) in the 
EEN and CS groups, respectively (p=0.313). No significant differences in PCDAI scores, laboratory variables, and 
growth parameters were noted between the two groups at post-induction. However, significant changes in albumin 
levels at post-induction were observed in the EEN group compared to the CS group (p=0.038).
Conclusion: Our results suggest that the effectiveness of EEN with a polymeric diet and CSs for induction therapy 
did not differ in Korean pediatric CD patients. EEN with a polymeric diet is a good first-line treatment option for the 
induction of remission in these patients.
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INTRODUCTION
Crohn’s disease (CD) is a lifelong chronic in-
flammatory disease of the gastrointestinal tract. 
Compared with adult-onset CD, pediatric CD is par-
ticularly characterized by rapid progression and ex-
tensive intestinal involvement at diagnosis [1]. 
Additionally, as children are in the growth phase, it 
is important to provide sufficient nutrients and min-
imize adverse effects associated with various drugs 
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Fig. 1. Flowchart of the study. 
EEN: exclusive enteral nutrition, PCDAI: Pediatric Crohn’s
Disease Activity Index, BMI: body mass index, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein.
for pediatric CD [2]. Corticosteroids (CSs) have long 
been used as a treatment for pediatric CD. However, 
to minimize adverse effects, exclusive enteral nu-
trition (EEN) is recommended as first-line treat-
ment for the induction of remission in children with 
CD [3]. EEN has recently become the preferred 
choice for induction therapy in pediatric CD in 
Europe but is less preferred in North America [4,5]. 
Previous studies have reported that the efficacy rate 
of EEN for the induction of remission is approx-
imately 70% to 80% [6-8].
Two types of EEN for induction therapy are avail-
able: monomeric and polymeric diets. A monomeric 
diet is more expensive and has fewer flavors than a 
polymeric diet, but no difference in efficacy has been 
identified between these two diets [9]. Thus, under 
general circumstances, a polymeric diet is recom-
mended for induction therapy. In a retrospective 
study, Soo et al. [10] showed the effectiveness of 
EEN (polymeric or semi-elemental) versus CSs for 
the induction of remission in pediatric CD patients. 
Although a polymeric diet tastes better and is less ex-
pensive than a monomeric diet, no study has re-
ported the effectiveness of a polymeric diet in Korean 
pediatric CD patients [11,12]. Moreover, the Korean 
government provides only a monomeric diet for in-
duction therapy in pediatric CD patients. 
The present study aimed to compare the effective-
ness of two therapeutic regimens (EEN with a com-
mercially available polymeric diet [EncoverⓇ; JW 
Pharmaceutical, Seoul, Korea] and CSs) for in-
duction therapy by analyzing both clinical and labo-
ratory variables in pediatric CD patients. 
MATERIALS AND METHODS
Study subjects and data collection
This study was a retrospective study conducted at 
Severance Hospital in Seoul, Korea, and Incheon St. 
Mary’s Hospital in Incheon, Korea, between 2005 
and 2017. Medical charts of newly diagnosed pedia-
tric CD patients who had received induction treat-
ment with either EEN or CSs were reviewed. Patients 
who lacked medical records or who had not adhered 
to either therapy during the induction period were 
excluded. Patient data, including baseline demo-
graphics, disease classification, Pediatric Crohn’s 
Disease Activity Index (PCDAI) score, height, 
weight, body mass index (BMI), hematocrit (Hct) 
level, erythrocyte sedimentation rate (ESR), C-re-
active protein (CRP) level, and albumin level, were 
collected before and after induction therapy. Disease 
location and behavior had been categorized accord-
ing to the Montreal classification [13]. 
Study design
Comparison was performed between those who 
had received either EEN (EEN group) or CS during 
induction (CS group). For the EEN group, a poly-
meric formula had been orally administered to in-
duce remission. The formula volume had been based 
on the estimated energy requirements for an ideal 
weight, with consideration of height. For the CS 
group, prednisone (1 mg/kg/day) had been initiated 
either intravenously or orally for 4 weeks and had 
been weaned over the subsequent 2 to 4 weeks (Fig. 
1). The primary endpoint was the rate of clinical re-
mission after 8 weeks of induction therapy with EEN 
or CSs. Clinical remission was defined as a PCDAI 
score ＜10 [14,15]. The secondary endpoints were 
changes in the following clinical and laboratory vari-
ables: PCDAI score, height Z-score, weight Z-score, 
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Sex, male 37/51 (72.5) 15/19 (78.9) 22/32 (68.8) 0.435
Age (y) 13.0 (3.0-17.0) 14.0 (9.0-17.0) 13.0 (3.0-17.0) 0.414
PCDAI 40.0 (12.5-60.0) 30.0 (12.5-60.0) 42.5 (15.0-60.0) 0.056
Disease location 0.130
  L1 6 (11.8)  (0.0) 6 (18.8)
  L2 5 (9.8) 3 (15.8) 2 (6.3)
  L3 38 (74.5) 16 (84.2) 22 (68.8)
  Any L4 involvement 5 (9.8) 1 (5.3) 4 (12.5)
Disease behavior 0.251
  B1 41 (80.4) 16 (84.2) 25 (78.1)
  B2 9 (17.6) 2 (10.5) 7 (21.9)
  B3 1 (1.9) 1 (5.3) 0 (0.0)
Perianal disease 22 (43.1) 11 (57.9) 11 (34.4) 0.101
Height Z score −0.12 (−3.51 to 2.55) 0.07 (−2.52 to 2.55) −0.30 (−3.51 to 1.65) 0.136
Weight Z score −1.19 (−3.77 to 2.21) −1.02 (−3.77 to 2.21) −1.28 (−3.61 to 1.00) 0.340
BMI Z score −1.43 (−3.35 to 2.11) −1.58 (−3.09 to 2.11) −1.31 (−3.35 to 1.26) 0.984
Hematocrit (%) 36.5 (27.0 to 44.1) 34.7 (27.0 to 44.1) 36.7 (27.9 to 41.8) 0.381
ESR (mm/h) 67.0 (2.0 to 120.0) 58.0 (17.0 to 98.0) 77.0 (2.0 to 120.0) 0.021
CRP (mg/L) 41.3 (0.4 to 160.0) 43.9 (2.5 to 96.2) 36.6 (0.4 to 159.9) 0.842
Albumin (g/dL) 3.3 (2.3 to 4.5) 3.3 (2.5 to 4.5) 3.4 (2.3 to 4.5) 0.538
Values are presented as number (%) or median (range). 
EEN: exclusive enteral nutrition, PCDAI: Pediatric Crohn’s Disease Activity Index, BMI: body mass index, ESR: erythrocyte 
sedimentations rate, CRP: C-reactive protein.
L1-4: terminal ileal±limited cecal disease (L1), colonic disease (L2), ileocolonic disease (L3), upper disease (L4). 
B1: non-stricturing and non-penetrating, B2: stricturing, B3: penetrating.
BMI Z-score, Hct level, ESR, CRP level, and albumin 
level. Growth status (i.e., height, weight, and BMI 
status) was assessed by calculating the Z-score using 
the 2017 Korean National Growth Chart for children 
and adolescents (http://www.cdc.go.kr). This study 
was approved by the institutional review board of 
Severance Hospital, Yonsei University, Seoul, South 
Korea, and Catholic Medical Center, The Catholic 
University of Korea, Seoul, South Korea.
Statistical analysis
The Mann-Whitney U-test was used to compare 
continuous variables between the EEN and CS groups. 
Differences before and after induction between both 
groups were compared using the Wilcoxon sign-
ed-rank test. Categorical variables were analyzed us-
ing the chi-square test or Fisher’s exact test. All stat-
istical analyses were performed using SPSS version 
23.0 (IBM Co., Armonk, NY, USA). A p-value ＜0.05 
was considered statistically significant.
RESULTS
Baseline characteristics
Between 2005 and 2017, a total of 85 pediatric pa-
tients were diagnosed with CD. Thirty-four patients 
who lacked medical records or who had not adhered 
to EEN or CS therapy during the induction period 
were excluded, leaving 51 patients for inclusion. 
Among these patients, 19 and 32 patients received 
EEN and CSs for induction therapy, respectively. 
Thirty-seven patients (72.5%) were male, and the 
median age at baseline was 13.0 years (range, 3.0-7.0 
years). Comparison of baseline characteristics be-
tween the two groups did not show significant dif-
ferences except ESR, which was significantly higher 
in the CS group compared to the EEN group (median 
77.0 vs. 58.0, p=0.021) (Table 1).
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Before After Before After
PCDAI 30.0 (12.5 to 60.0) 2.5 (0 to 37.5) ＜0.001 42.5 (15 to 60) 5.0 (0 to 28) ＜0.001
Hematocrit (%) 34.7 (27.0 to 44.1) 39.8 (35.9 to 45.5) 0.001 36.7 (27.9 to 41.8) 40.0 (31.7 to 48.7) 0.001
ESR (mm/h) 58.0 (17 to 98) 19.0 (6 to 47) ＜0.001 77.0 (2 to 120) 25.0 (3 to 83) ＜0.001
CRP (mg/L) 43.9 (2.5 to 96.2) 2.2 (0.2 to 23.6) ＜0.001 36.6 (0.4 to 160.2) 2.0 (0.3 to 113.0) ＜0.001
Albumin (g/dL) 3.3 (2.5 to 4.5) 4.3 (3.3 to 4.8) ＜0.001 3.5 (2.3 to 4.5) 4.0 (3.1 to 4.8) ＜0.001
Height Z-score 0.1 (−2.52 to 2.55) 0 (−2.62 to 2.52) 0.227 −0.3 (−3.51 to 1.65) −0.3 (−3.52 to 1.26) 0.262
Weight Z-score −1.0 (−3.77 to 2.21) −0.7 (−3.12 to 1.86) 0.010 −1.3 (−3.61 to 1.00) −0.9 (−3.51 to 1.00) 0.001
BMI Z-score −1.6 (−3.09 to 2.11) −0.9 (−2.09 to 1.73) 0.008 −1.3 (−3.35 to 1.26) −0.9 (−3.82 to 2.90) 0.001
Values are presented as median (range).
EEN: exclusive enteral nutrition, PCDAI: Pediatric Crohn’s Disease Activity Index, ESR: erythrocyte sedimentation rate, CRP: 
C-reactive protein, BMI: body mass index.




Clinical remission rate 36/51 (70.6) 15/19 (78.9) 21/32 (65.6) 0.313
Disease location
  L1 4/6 (66.7) 0/0 (0.0) 4/6 (66.7) –
  L2 5/5 (100) 3/3 (100) 2/2 (100) –
  L3 25/38 (67.6) 12/16 (75.0) 13/22 (54.5) 0.307
Any L4 involvement 4/5 (80.0) 1/1 (100) 3/4 (75.0) 1.000
Disease behavior
  B1 29/41 (70.7) 12/16 (75.0) 17/25 (68.0) 0.734
  B2 6/9 (66.7) 2/2 (100) 4/7 (57.1) 0.500
  B3 1/1 (100) 1/1 (100) 0/0 (0.0) –
Perianal disease 16/22 (72.7) 7/11 (63.6) 9/11 (81.8) 0.635
Values are presented as number (%).
EEN: exclusive enteral nutrition. 
L1-4: terminal ileal±limited cecal disease (L1), colonic disease (L2), ileocolonic disease (L3), upper disease (L4). 
B1: non-stricturing and non-penetrating, B2: stricturing, B3: penetrating.
Clinical remission was defined as a pediatric Crohn’s disease activity index score ＜10.
Comparison of clinical remission rates between 
the EEN and CS group
The overall clinical remission rate was 70.6% 
(36/51) after induction. Fifteen of 19 patients 
(78.9%) in the EEN group and 21 of 32 patients 
(65.6%) in the CS group were in clinical remission af-
ter induction (p=0.313). Furthermore, clinical re-
mission rates according to disease location, luminal 
behavior and perianal disease did not significantly 
differ between the two groups (Table 2).
Comparison between pre- and post-induction 
variables in each group
In the EEN group, all clinical and laboratory varia-
bles except for height Z-score significantly improved 
after induction therapy. PCDAI scores, Hct levels, ESR, 
and CRP levels significantly decreased (p＜0.05), 
whereas weight Z-scores, BMI Z-scores, and albumin 
levels significantly increased (p＜0.05) after induction 
therapy. Additionally, similar results were noted in the 
CS group after induction (p＜0.05) (Table 3).
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ΔPCDAI −32.5 (−57.5 to 5.0) −30.0 (−52.5 to 5.0) −33.8 (−57.5 to −7.5) 0.446
ΔHeight Z-score 0 (−0.40 to 1.49) 0 (−0.16 to 0.17) 0 (−0.40 to 1.49) 0.599
ΔWeight Z-score +0.3 (−0.51 to 1.95) +0.3 (−0.51 to 0.99) +0.3 (−0.32 to 1.95) 0.892
ΔBMI Z-score +0.3 (−1.23 to 2.18) +0.3 (−0.58 to 1.35) +0.3 (−1.23 to 2.18) 0.668
ΔHematocrit (%) +2.9 (−5.40 to 14.20) +4.6 (−1.60 to 11.80) +2.9 (−5.40 to 14.20) 0.212
ΔESR (mm/h) −37 (−108 to 12) −32.0 (−64 to 2) −37.0 (−108 to 12) 0.298
ΔCRP (mg/L) −37.2 (−159.24 to 108.08) −43.4 (−84.23 to 2.45) −35.2 (−159.24 to 108.08) 0.837
ΔAlbumin (g/dL) +0.7 (−0.30 to 1.60) +1.0 (0.0 to 1.60) +0.5 (−0.30 to 1.50) 0.038
Values are presented as median (range).
EEN: exclusive enteral nutrition, PCDAI: Pediatric Crohn’s Disease Activity Index, BMI: body mass index, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein.
Comparison of changes in variables between 
the two groups
Differences in clinical variables before and after 
the induction of remission between the two groups 
are shown in Table 4. There were no significant dif-
ferences between both groups in the clinical re-
mission rate, PCDAI score, Hct level, ESR, CRP level, 
height Z-score, weight Z-score, and BMI Z-score be-
fore and after induction. However, albumin levels in 
the EEN group significantly improved after in-
duction compared with that in the CS group 
(p=0.038) (Table 4).
DISCUSSION
This study showed that the effects of EEN with a 
polymeric diet did not differ from those of CSs for the 
induction of remission in Korean pediatric CD 
patients. Clinical remission rates after 8 weeks of in-
duction therapy were not significantly different be-
tween pediatric CD patients treated with CSs and 
EEN (65.6% vs. 78.9%, p=0.318). Our results suggest 
that EEN with a polymeric diet is as effective as CSs 
for the induction of remission in Korean pediatric CD 
patients. 
The management strategy for pediatric CD is 
evolving. Managing pediatric CD does not simply in-
volve the induction of remission but considers 
growth and pubertal development, and it is neces-
sary to minimize adverse effects due to drugs and 
disease complications [16]. Thus, it is more difficult 
for physicians to provide a management plan for pe-
diatric CD patients. Although the exact mechanism 
of EEN is unclear, it has been widely used in pediatric 
CD patients as an induction therapy because it is as-
sociated with few complications and is effective with 
respect to growth and pubertal development [17].
In 2014, the European Crohn’s and Colitis 
Organisation (ECCO) and the European Society for 
Paediatric Gastroenterology, Hepatology, and 
Nutrition (ESPGHAN) issued consensus guidelines 
that recommend EEN as first-line therapy for the in-
duction of remission in children with active CD [3]. 
According to the ECCO/ESPGHAN guideline, the use 
of CSs should be avoided in children whenever possi-
ble owing to their adverse effects, while oral CSs for 
induction therapy can be an option when children 
with moderate to severe active luminal CD cannot 
adhere to EEN [3,11]. Furthermore, previous studies 
have shown that CSs do not improve endoscopic and 
histologic inflammatory lesions despite their benefi-
cial effect on clinical response [18,19].
A previous study by Grover et al. [20] showed the 
efficacy of EEN for inducing clinical remission 
(84%), mucosal remission (58%), and transmural re-
mission (21%) in pediatric CD. Furthermore, early 
good endoscopic response with EEN induction led to 
decreased relapse, hospitalization, need for anti-tu-
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mor necrosis factor therapy, and surgical resection at 
1 year [20]. Several retrospective studies have sug-
gested that EEN is not only capable of inducing clin-
ical remission but also of improving bone metabo-
lism, increasing muscle mass, and decreasing viscer-
al fat [21,22]. Therefore, with many such advan-
tages, EEN has become the preferred induction ther-
apy worldwide [23]. 
In a randomized controlled trial in 2006, Borrelli et 
al. [11] showed comparable clinical remission rates 
for EEN with a polymeric diet (79%) and CS therapy 
(67%). The present study obtained similar results, 
with a clinical remission rate of 78.9% and 65.6% for 
EEN and CSs, respectively. Day et al. [24], in a sys-
temic review in 2008, showed that disease location 
can affect the efficacy of EEN. However, Buchanan et 
al. [25] indicated that disease phenotype does not af-
fect clinical remission and suggested that EEN 
should be offered to all pediatric CD patients. 
Furthermore, Day et al. [26] reported that EEN can 
also be beneficial to children with perianal disease, 
whether alone or in combination with luminal 
disease. The association between disease location 
and treatment outcomes of EEN was not observed in 
our study. 
Although several studies have suggested EEN 
with a polymeric diet as a first-line treatment for CD, 
our study is the first to show its effects in Korean 
children [3,11,27]. The findings of our study suggest 
that the same results could be obtained with EEN us-
ing a specific polymeric product regardless of 
ethnicity. Furthermore, because only the effect of 
EEN with a monomeric diet has been confirmed in 
Korean adolescents, the government has funded on-
ly the monomeric diet in children with CD in Korea 
[12]. As the effectiveness of EEN with a polymeric 
diet has been confirmed by this study, patients are 
expected to choose from a variety of EEN formulas to 
suit their taste. Additionally, because a polymeric di-
et is less expensive and tastes better than a mono-
meric diet, this may increase the success rate of EEN 
with a polymeric diet [12]. 
The present study has some limitations. First, it 
was not a prospective randomized controlled trial. 
Thus, there might have been a selection bias that 
could have affected the results. In this study, the CS 
group had a higher PCDAI score and ESR than the 
EEN group before induction. Patients with more se-
vere disease activity may have received CSs for in-
duction therapy, which may have resulted in the in-
troduction of a selection bias. Second, colonoscopy 
findings or fecal calprotectin levels were not 
assessed. Mucosal healing has recently emerged as 
the optimal treatment target in CD management. 
Thus, endoscopic evaluation and treatment opti-
mization are crucial in the current era of treat-to-tar-
get [28,29]. Third, only short-term follow-up results 
were included. Moreover, we were unable to inves-
tigate the adverse events of both treatments owing to 
the retrospective character of this study and the 
short-term follow-up period. Fourth, due to the lack 
of information on the small bowel in some patients, 
analysis results according to disease location may 
not be accurate. Despite these limitations, our study, 
to our knowledge, is the first to evaluate the effec-
tiveness of EEN with a polymeric diet for the in-
duction of remission in Korean children with active 
CD.
In conclusion, EEN with an oral polymeric diet 
was not inferior to CSs for the induction of remission 
in Korean children with CD. Induction therapy with 
polymeric EEN should be considered as first-line 
treatment along with monomeric EEN in these pa-
tients, considering the well-known adverse events 
associated with CS treatment. 
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